<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03174002</url>
  </required_header>
  <id_info>
    <org_study_id>AAUH-ICU-01</org_study_id>
    <secondary_id>2017-000632-34</secondary_id>
    <nct_id>NCT03174002</nct_id>
  </id_info>
  <brief_title>Handling Oxygenation Targets in the Intensive Care Unit</brief_title>
  <acronym>HOT-ICU</acronym>
  <official_title>Handling Oxygenation Targets in Adults With Acute Hypoxaemic Respiratory Failure in the Intensive Care Unit: A Randomised Clinical Trial of a Lower Versus a Higher Oxygenation Target</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen Trial Unit, Center for Clinical Intervention Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aalborg University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Handling oxygenation targets (HOT) is standard of care in the intensive care unit (ICU),
      however the quality and quantity of evidence is low and potential harm has been reported. The
      aim of the HOT-ICU trial is to assess the overall benefits and harms of two levels of
      oxygenation targets in adult critically ill patients with acute hypoxaemic respiratory
      failure in the ICU.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acutely ill adults with hypoxaemic respiratory failure admitted to the intensive care unit
      (ICU) are at risk of life-threatening hypoxia, and thus oxygen is administered. However, the
      evidence on the optimal level of oxygenation is of low quantity and quality with no firm
      evidence for benefit or harm. Importantly, liberal use of supplementary oxygen may increase
      the number of serious adverse events including death. The aim of the HOT-ICU trial is to
      assess the benefits and harms of two targets of partial pressure of oxygen in arterial blood
      (PaO2) in guiding the oxygen administration in acutely ill adults with hypoxaemic respiratory
      failure at ICU admission.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>90-days mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Landmark mortality 90-days after randomisation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days alive without organ support</measure>
    <time_frame>Within 90 days</time_frame>
    <description>Percentage of days alive and free from mechanical ventilation, circulatory support and renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive out of the hospital</measure>
    <time_frame>Within 90 days</time_frame>
    <description>Percentage of days alive out of the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with one or more serious adverse events</measure>
    <time_frame>Until ICU discharge, maximum 90 days</time_frame>
    <description>Serious adverse events are defined as new episode of shock and new episodes of ischaemic events including myocardial or intestinal ischaemia or ischaemic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Landmark mortality 1 year after randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessement using the EuroQual-5D-5L telephone interview in selcted sites</measure>
    <time_frame>1 year</time_frame>
    <description>EQ-5D-5L 1-year after randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function 1-year after randomisation as assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) score in selected sites</measure>
    <time_frame>1 year</time_frame>
    <description>RBANS score 1 year after randomisation at selected sites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>1 year</time_frame>
    <description>Bodyplethysmography and carbon monooxide diffusion capacity 1 year after randomisation at sellected sites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A health economic analysis</measure>
    <time_frame>90 days</time_frame>
    <description>The analytic details will be based on the result of the trial and specified (cost-effectiveness versus cost-minimisation analyses)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2928</enrollment>
  <condition>Hypoxemic Respiratory Failure</condition>
  <condition>Oxygen Toxicity</condition>
  <arm_group>
    <arm_group_label>Low oxygenation target</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Partial pressure of oxygen in arterial blood (PaO2) 8 kPa (60 mmHg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High oxygenation target</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Partial pressure of oxygen in arterial blood (PaO2) 12 kPa (90 mmHg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>Oxygen administration to achieve a PaO2 of 8 kPa (60 mmHg) from ICU admission to ICU discharge</description>
    <arm_group_label>Low oxygenation target</arm_group_label>
    <other_name>Inspired oxygen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>Oxygen administration to achieve a PaO2 of 12 kPa (90 mmHg) from ICU admission to ICU discharge</description>
    <arm_group_label>High oxygenation target</arm_group_label>
    <other_name>Inspired oxygen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acutely admitted to the ICU AND

          -  Aged ≥ 18 years AND

          -  Receives supplemental oxygen with a flow of at least 10 L per minutes in an open
             system including high-flow systems OR at least a FiO2 of 0.50 in a closed system
             including invasive or non-invasive ventilation or CPAP systems AND

          -  Expected to receive supplemental oxygen for at least 24 hours in the ICU AND

          -  Having an arterial line for PaO2 monitoring

        Exclusion Criteria:

          -  Cannot be randomised within twelve hours after present ICU admission

          -  Chronic mechanical ventilation for any reason

          -  Use of home oxygen

          -  Previous treatment with bleomycin

          -  Organ transplant during current hospital admission

          -  Withdrawal from active therapy or brain death deemed imminent

          -  Fertile woman (&lt; 50 years of age) with positive urine human gonadotropin (hCG) or
             plasma-hCG

          -  Carbon monoxide poisoning

          -  Cyanide poisoning

          -  Methaemoglobinaemia

          -  Paraquat poisoning

          -  Any condition expected to involve the use of hyperbaric oxygen (HBO)

          -  Sickle cell disease

          -  Consent not obtainable according to national regulations

          -  Previously randomised into the HOT-ICU trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bodil Steen Rasmussen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg University Hospital, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anders Perner, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bodil Steen Rasmussen, MD, PhD</last_name>
    <phone>+4597661864</phone>
    <email>bodil.steen.rasmussen@rn.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olav Lilleholt Schjørring, MD</last_name>
    <phone>+4597661921</phone>
    <email>o.schjoerring@rn.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olav L Schjørring, MD</last_name>
      <email>o.schjoerring@rn.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care East Section, Øst, Skejby, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans M Betsch, MD</last_name>
      <email>hansbets@rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care Section Nord, Skejby, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars H Østergaard, MD</last_name>
      <email>lasnel@rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, University Hospital Skejby</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care 4131, Copenhagen University Hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bjørn Brand, MD</last_name>
      <email>bjoern.brand@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian S Meyhoff, MD</last_name>
      <email>christian.saltholt.meyhoff@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne S Andreasen, MD</last_name>
      <email>anne.sofie.andreasen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Herning Hospital</name>
      <address>
        <city>Herning</city>
        <zip>7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Winding, MD</last_name>
      <email>robewing@rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Hillerød Hospital</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Bestle, MD, PhD</last_name>
      <email>morten.bestle@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Hjørring Hospital</name>
      <address>
        <city>Hjørring</city>
        <zip>9800</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrei Ciubotariu, MD</last_name>
      <email>anci@rn.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Holbæk Hospital</name>
      <address>
        <city>Holbæk</city>
        <zip>4300</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans H Bülow, MD</last_name>
      <email>hhbu@regionsjaelland.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Intensive Care, Holstebro</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nilanjan Dey, MD</last_name>
      <phone>+4578432827</phone>
      <email>nildey@rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Holstebro Hospital</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nilanjan Dey, MD</last_name>
      <email>nildey@rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Horsens Hospital</name>
      <address>
        <city>Horsens</city>
        <zip>8700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lone Buus, MD</last_name>
      <phone>+4578425000</phone>
      <email>lonebuus@rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulf G Pedersen, MD</last_name>
      <email>ulf.goettrup.pedersen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Kolding Hospital</name>
      <address>
        <city>Kolding</city>
        <zip>6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane S Nielsen, MD</last_name>
      <email>jane.stab.nielsen@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Køge Hospital</name>
      <address>
        <city>Køge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerij Khridin, MD</last_name>
      <email>vkh@regionsjaelland.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Randers Hospital</name>
      <address>
        <city>Randers</city>
        <zip>8930</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thorbjørn Grøfte, MD</last_name>
      <email>thorgroe@rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Roskilde Hospital</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Hildebrandt Walli, MD</last_name>
      <email>thi@regionsjaelland.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Slagelse Hospital</name>
      <address>
        <city>Slagelse</city>
        <zip>4200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne A Iversen, MD</last_name>
      <email>saiv@regionsjaelland.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Department of Intensive Care, Viborg Hospital</name>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoffer G Sølling, MD</last_name>
      <email>chrsoell@rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjatta Okkonen, MD</last_name>
      <email>marjatta.okkonen@hus.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Central Finland Central Hospital</name>
      <address>
        <city>Jyväskylä</city>
        <zip>40620</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anni Pulkkinen, MD</last_name>
      <email>anni.pulkkinen@ksshp.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Kuopio University Hospital, Kuopio</name>
      <address>
        <city>Kuopio</city>
        <zip>70210</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilkka Parviainen, MD</last_name>
      <email>ilkka.parviainen@kuh.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Turku University Hospital, Turku</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juha Grönlund, MD</last_name>
      <email>juha.gronlund@tyks.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Landspitali University Hospital Reykjavik</name>
      <address>
        <city>Reykjavík</city>
        <country>Iceland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin M Thormar, MD</last_name>
      <email>katrinthormar@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Keus, MD</last_name>
      <email>f.keus@umcg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Canisius Wilhelmina Hospital</name>
      <address>
        <city>Nijmegen</city>
        <zip>6532 SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Hoiting, MD</last_name>
      <email>o.hoiting@cwz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, National Hospital, University of Oslo</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon H Laake, MD</last_name>
      <email>jhlaake@me.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Basel University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>4056</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Siegemund, MD</last_name>
      <email>martin.siegemund@usb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joerg C Schefold, MD</last_name>
      <email>joerg.schefold@insel.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Berkshire NHS Foundation Trust</name>
      <address>
        <city>Reading</city>
        <state>Berkshire</state>
        <zip>RG1 5AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Walden, MD</last_name>
      <email>andrew.walden@royalberkshire.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Intensive Care, University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Morgan, MD</last_name>
      <email>morganmp@cardiff.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kingston Hospital NHS Foundation Trust</name>
      <address>
        <city>Kingston Upon Thames</city>
        <zip>KT2 7QB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Joseph, MD</last_name>
      <email>anna.joseph1@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Glamorgan Hospital</name>
      <address>
        <city>Llantrisant</city>
        <zip>CF72 8XR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ceri Lynch, MD</last_name>
      <email>Ceri.Lynch5@wales.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manchester University NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Sharman, MD</last_name>
      <email>mike.sharman@mft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Alexander, MD</last_name>
      <email>peter.alexander@mft.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Iceland</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.cric.nu/hot-icu/</url>
    <description>Link to the HOT-ICU website</description>
  </link>
  <reference>
    <citation>Schjørring OL, Perner A, Wetterslev J, Lange T, Keus F, Laake JH, Okkonen M, Siegemund M, Morgan M, Thormar KM, Rasmussen BS; HOT-ICU Investigators. Handling Oxygenation Targets in the Intensive Care Unit (HOT-ICU)-Protocol for a randomised clinical trial comparing a lower vs a higher oxygenation target in adults with acute hypoxaemic respiratory failure. Acta Anaesthesiol Scand. 2019 Aug;63(7):956-965. doi: 10.1111/aas.13356. Epub 2019 Mar 18. Review.</citation>
    <PMID>30883686</PMID>
  </reference>
  <reference>
    <citation>Barbateskovic M, Schjørring OL, Jakobsen JC, Meyhoff CS, Rasmussen BS, Perner A, Wetterslev J. Oxygen supplementation for critically ill patients-A protocol for a systematic review. Acta Anaesthesiol Scand. 2018 Aug;62(7):1020-1030. doi: 10.1111/aas.13127. Epub 2018 Apr 30.</citation>
    <PMID>29708586</PMID>
  </reference>
  <reference>
    <citation>Barbateskovic M, Schjørring OL, Russo Krauss S, Jakobsen JC, Meyhoff CS, Dahl RM, Rasmussen BS, Perner A, Wetterslev J. Higher versus lower fraction of inspired oxygen or targets of arterial oxygenation for adults admitted to the intensive care unit. Cochrane Database Syst Rev. 2019 Nov 27;2019(11). doi: 10.1002/14651858.CD012631.pub2.</citation>
    <PMID>31773728</PMID>
  </reference>
  <reference>
    <citation>Rasmussen BS, Perner A, Wetterslev J, Meyhoff CS, Schjørring OL. Oxygenation targets in acutely ill patients: still a matter of debate. Lancet. 2018 Dec 8;392(10163):2436-2437. doi: 10.1016/S0140-6736(18)32201-3.</citation>
    <PMID>30527413</PMID>
  </reference>
  <reference>
    <citation>Schjørring OL, Klitgaard TL, Perner A, Wetterslev J, Lange T, Keus F, Laake JH, Morgan M, Bäcklund M, Siegemund M, Thormar KM, Rasmussen BS. The handling oxygenation targets in the intensive care unit (HOT-ICU) trial: Detailed statistical analysis plan. Acta Anaesthesiol Scand. 2020 Jul;64(6):847-856. doi: 10.1111/aas.13569. Epub 2020 Mar 4.</citation>
    <PMID>32068884</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 30, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2017</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University Hospital</investigator_affiliation>
    <investigator_full_name>Bodil Steen Rasmussen</investigator_full_name>
    <investigator_title>Clinical Professor, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Oxygenation</keyword>
  <keyword>Acute Respiratory Distress Syndrome</keyword>
  <keyword>Mechanical ventilation</keyword>
  <keyword>Critical illness</keyword>
  <keyword>Critical care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All original records (incl. consent forms, eCRFs, and relevant correspondences) will be archived at trial sites for 15 years. The clean electronic trial database file will be delivered to the EudraCT Database and Zenodo (https://zenodo.org/about) and maintained for 15 years and anonymised if requested by the authorities.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Study Protocol and Statistical Analysis Plan has been published. Informed Consent Form are available on the webpage (www.cric.nu/hot-icu)</ipd_time_frame>
    <ipd_access_criteria>Managed by the Steering Committee of the HOT-ICUT trial.</ipd_access_criteria>
    <ipd_url>https://www.cric.nu/hot-icu/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

